Why Immunome Stock Surged Today

Core Insights - Immunome's shares increased by over 15% following positive clinical results for varegacestat, a treatment for desmoid tumors [1] Group 1: Disease Overview - Desmoid tumors are diagnosed in 1,000 to 1,650 individuals annually in the U.S. and can cause significant physical and emotional distress due to their unpredictable nature and limited treatment options [3] Group 2: Clinical Trial Results - The phase 3 clinical trial for varegacestat achieved its primary endpoint, showing an 84% reduction in the risk of disease progression or death compared to placebo [4] - All key secondary endpoints were also met, including reductions in tumor volume and pain intensity [4] - Varegacestat was generally well tolerated, with common side effects including diarrhea, fatigue, rash, nausea, and cough [4] Group 3: Market and Future Plans - Based on the trial results, Immunome plans to submit a New Drug Application to the FDA in Q2 2026 [6] - The current market capitalization of Immunome is $1.8 billion, with a gross margin of 71.34% [6]